Ophthalmic NSAID Prescription Fulfillment: A Roundtable Discussion

Article

Ophthalmic NSAIDs: A Pharmacist Roundtable

 Because cataract surgery is one of the most common types of the most common types of eye surgery in the United States, pharmacists from several states met to discuss the best options for ophthalmic NSAID eye drops. There are several NSAIDs and corticosteroid products used to control postoperative inflammation and pain, and the panel discussed best practices for choosing a product, fulfilling the prescription, and building good relationships between pharmacists and ophthalmologists. 

123Download the Supplement

 

 

Recent Videos
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Q&A: What AI Is, How It’s Helping Pharmacies with Compliance | NCPDP 2025

Q&A: What AI Is, How It’s Helping Pharmacies with Compliance | NCPDP 2025

Brian Nowosielski;Stanley V. Campbell, Jr;Yi Deng, PhD
May 9th 2025
Article

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss the basics of AI and how it’s assisting with compliance.

Demystifying PBMs, Their Role in the Drug Supply Chain

Demystifying PBMs, Their Role in the Drug Supply Chain

Brian Nowosielski;Antonio Ciaccia
May 8th 2025
Podcast

President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.

Roflumilast Foam Improves Symptoms of Scalp, Body Psoriasis

Roflumilast Foam Improves Symptoms of Scalp, Body Psoriasis

Killian Meara
May 8th 2025
Article

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

Scripted for Her: Helping Patients Choose Contraceptive Methods

Scripted for Her: Helping Patients Choose Contraceptive Methods

Killian Meara;Natalie DiPietro Mager, PharmD, PhD;Jasmine Cutler, PharmD, CPh
May 7th 2025
Podcast

In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.

Tremfya Demonstrates Sustained Response Up to 92 Weeks

Tremfya Demonstrates Sustained Response Up to 92 Weeks

Ashley Gallagher
May 8th 2025
Article

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Calories to Satiation Predicts Patients Likely to Experience Adverse Events From GLP-1s

Calories to Satiation Predicts Patients Likely to Experience Adverse Events From GLP-1s

Ashley Gallagher
May 7th 2025
Article

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

© 2025 MJH Life Sciences

All rights reserved.